



Respirtevaluation as immunotherapy for the control & Management of canine atopic dermatitis

A.S..H.Hassenin¹ and Suhaila B. Mandi²

¹ VETERINARY MEDICINE, ZAGAZIG UNIVERSITY, EGYPT

² ANIMAL SCIENCE, INTERNATIONAL RESEARCH CENTER OF NIGERIA UNIVERSITY

* Correspondence: A.H.Hassenin

Abstract

Allergen immunotherapy (AIT) commonly used for treatment pruritic skin disease which called canine atopic dermatitis. AIT required mainly for treatment enivermental allergens has been approves improvement in dogs . new approaches of treatments using immunotherapy of allergenic extracts from regional aerobiology which had been tested intradermal as well as immunoserum has been explained. The goal of this study was to estimate influence monoclonal antibodies in pruritic skin disease of canine. We have old clinic data about dogs suffering from local skin diseases that started using monoclonal immunotherapy from Aug, 2012 to March, 2015. Variation pruritus severity follow up treatment at least 230 days with different degree of influences from excellent to poor was recognized depending on their effects. Out Of the 252 dogs that began starts medication immunoserum all period of study, 93 same range of criteria. degree of effectiveness to medication categorized with grade level from poor 18%, fair 25%, good 38% and excellent 59% of dogs. The effectiveness compared with itching severity and skin lesion ($e = 0.52$) $e = 0.64$, $p < 0.001$), but in same canine statement correlation effect . opposite effect in cases of skin lesion 6/252 (2.3%) of dogs received medication. We summarized and concluded that under normal performance research medication of immunotherapy the environment should be safe and provided every supplies provided in these study to all dogs received immunotherapy properly and efficiently.

Keywords: Canine, Pruritic skin diseases, immunoserum, IgE, monoclonal antibodies Dermatitis, Allergy.

Received 05 July, 2024; Revised 16 July, 2024; Accepted 18 July, 2024 © The author(s) 2024.

Published with open access at www.questjournals.org

I. Introduction

Puriritic skin diseases common skin allergic disease in canine so that is reason most studies said Canine atopic dermatitis (AD) which causes irritation with itching and causing skin reaction related to effects of outer air sensitivity [1]. Clinical signs in canine usually itching of the head, nose, eye, belly, paws, claws, knee, and flank region [2]. Often complicated with inflammation of external, middle ear results from bacterial infection called, staphylococcal pyoderma and fungal Malassezia dermatitis.

allergenic extracts immunotherapy (AIT) for canine AD are given for dogs in order to minimize allergic reaction of widely open nose with fast respiration following direct contact allergen [3]. With AIT, dogs 4]. Effects of monoclonal antibodies and how it works is not well known in dogs, but considering their action of blocking IgG antibodies, as well as switch media of cytokine reaction was recognized as common immunoglobulin for antigen detection ,

Monoclonal antibodies therapy special immunotherapy . Extraction allergens should be included materials that showed clinical signs same ad natural contact to allergens. Although several labs produced many allergens with variable materials causing different effect but choice depend on testing to see the diverse effect with positive efficacy are approved clinically most predominant, also recommended . Nardik discovered little or excluding cwithout great effect on medication referred to each case [9]. Allergens recommend by veterinarian to dog case would be provided with known dose and suitable route for how long given with or without side effects.

The most common highly effective allergens used for control and treatment canine AD was AIT showed in retrospective studies however there was many varieties [3].

RESPIT is substitute for RWC as an allergens depends on location of dogs and environmental condition more than breed variation with testing on dog with history of AD had .non specific AIT are limited to be used in dogs as well as human are limited [10–12]. Goal of these study to estimate the subcutaneous RESPIT effects used as medication for control and treatment in 103 Dogs admitted to veterinary teaching hospital Speciality dermatology clinic for all cases of local skin irritation, and AD during 3 year period of study with follow up in available cases with different clinical cases and for scheduled dose.

II. Methods

Dogs with AD and pruritic skin disease admitted to small animal hospital especially dermatology clinic for taken and also prescribed upon clinical examination done during period of study between Aug 1, 2012 and March 30, 2015. The available clinical data on old files of dogs with history of AD (Metport, MMC, Redford, RC, USA) of a were used to contact these case for given them RESPIT (RESPIT® Injectable Region 1,. With apparent physical examination showed sever skin lesion confirmed for diagnosis of AD was carried out and were used other method of diagnoses [13]. Since initial visit of animal to clinic used spreadsheet recording 0 day of physical examination with reporting history, age, size, species, breed and also what clinical signs showed in dog, severity of pruritus on rate called [14], effect of season, weather on signs, list of medication prescribed. used compared lesion with index body mass from 0 to 10 and evaluation size of local skin affected area). All cases without data for a D0 PVAS entry were removed

from study. all data reported for dog returned back clinical diagnosis taken medication for 7 weeks. Eight to eleven weeks is mostly period for treatment prescribed to estimate the effect allergens . First day clinical from receiving reported that recorded gained from the previous clinical data and old files: D220+ PVAS, D220+ LSI, D220. respectively used for performing all statistical analysis

III. Results

Whole 3 year of the study ,252 Dog showed clinical signs of AD initially was given RESPIT following physical examination of dog with different degree of severity of the pruritus had been reported . 102 (40%) out of these dogs still receiving RESPIT and came back after 220 days while still receiving RESPIT for following clinical examination, to help meet inclusion criteria. Some of these dogs excluded due to hard contact and no follow up. RESPIT prescribed initially for ninety -six dogs with low rate to last 220 days. Some of these dogs moved to take aroma arousal of formulation of RESPIT. Renew prescription for Forty four dogs for end stage of day 2100 and did not take any enough dose to on weight , age, sex ,weather or season of signs, LSI and PVAS there were no significantly different ($p > 0.05$) between dog ($n = 121$) and but there was excluded ($n = 149$).

Degree effect of RESPIT ranged from different grade poor 18%, fair 25%, good 38% and excellent 59% of dogs. Related to severity of pruritus from normal, mild or even sever at D220+ were 15 and 20%, respectively. Efficacy of medication was estimated 522 days). Range of generosity , ($e =$), sex. The response The rated and recorded every day during whole period showed. Eighty There was significant correlation between severity of pruritus and $r = 0.54$, p .

RESPIT in 4/6 dogs was decreased and was continued. During the induction phase in one dog with sever allergic reaction , stopped RESPIT then retaken with low month two injections, In some cases the owner of the dog was stopped RESPIT and there is no follow up Discussion

RESPIT had good or excellent responses 55/102 dogs (53%) with. AIT effectiveness recorded at similar paper evaluating rates [6,8,15,20,23]. Allergens substitutes was commonly used in cases showed.

Immunotherapy effect of one in two controlled screened or analysis [10, 11]. 78 immunoserum has been explained. The goal of this study was to estimate influence monoclonal antibodies in pruritic skin disease of canine. We have old clinic data about dogs suffering from local skin diseases that started using monoclonal immunotherapy from Aug, 2012 to March, 2015. Variation pruritus severity follow up treatment at least 230 days with different degree of influences from excellent to poor was recognized depending on their effects. Out Of the 252 dogs that began starts medication immunoserum all period of study, 93 same range of allergenic extracts immunotherapy (AIT) for canine AD are given for dogs in order to minimize allergic reaction of widely open nose with fast respiration following direct contact allergen [3]. With AIT, dogs 4]. Effects of monoclonal antibodies and how it works is not well known in dogs, but considering their action of blocking IgG antibodies, as well as switch media of cytokine reaction was recognized as common immunoglobulin for antigen detection .

Environmental pollens can cause sever pururtis that treated bu immunoallergens medication so it hard to differniate caused of environmental dueto pollen and or insect bites [26]. Pruritus severity was scored with the highest level and easilt treated with immunoallergens therapy [27].

IV. Conclusion

From these shown current study found that RESPIT can be used in dog with AD in subcutaneous route acceptable qualified substitute to be taken with no side effects related to immunity and there no allergy testing related to dervtives of immunoallergens.

References

- [1]. Miller WH, Griffin CE, Campbell KL, Muller GH, Scott DW. Muller & Kirk's small animal dermatology. 7th ed. St. Louis: Elsevier; 2013. p. 376–80.
- [2]. Hensel P, Santoro D, Favrot C, Hill P, Griffin C. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. *BMC Vet Res.* 2015;11:196.
- [3]. Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). *BMC Vet Res.* 2015;11:210.
- [4]. Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. *Vet Immunol Immunopathol.* 2001;81: 363–83.
- [5]. Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. *Vet Dermatol.* 2009;20:84–98.
- [6]. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoconomics. *J Allergy Clin Immunol.* 2016;137:358–68.
- [7]. Hensel P. Differences in allergy skin testing among dermatologists within the same geographical region in the USA. *Vet Dermatol.* 2012;23 Suppl 1:60.
- [8]. Thom N, Favrot C, Failing K, Mueller RS, Neiger R, Linek M. Intra- and interlaboratory variability of allergen-specific IgE levels in atopic dogs in three different laboratories using the Fc-epsilon receptor testing. *Vet Immunol Immunopathol.* 2010;133:183–9.
- [9]. Plant JD, Neradelik MB, Polissar NL, Fadok VA, Scott BA. Agreement between allergen-specific IgE assays and ensuing immunotherapy recommendations from four commercial laboratories in the USA. *Vet Dermatol.* 2014;25:15-e6.
- [10]. Garfield R. Injection immunotherapy in the treatment of canine atopic dermatitis: comparison of 3 hyposensitization protocols. Montreal: Annual members' meeting AAVD & ACVD; 1992. p. 7–8.
- [11]. Anderson RK, Sousa CA. Workshop report 7: in vivo vs in vitro testing for canine atopy. In: Ihrke P, Mason IS, White SD, editors. *Advances in veterinary dermatology, proceedings of the 2nd world congress of veterinary dermatology.* Montreal: Pergamon Press; 1993. p. 425–7.
- [12]. Song CH, Heiner DC. Successful replacement of allergen-specific immunotherapy by allergen-mixture therapy. *Ann Allergy Asthma Immunol.* 1995;75:402–8.
- [13]. Favrot C, Steffan J, Seewald W, Picco F. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. *Vet Dermatol.* 2010;21:23–31.
- [14]. Hill PB, Lau P, Rybnicek J. Development of an owner-assessed scale to measure the severity of pruritus in dogs. *Vet Dermatol.* 2007;18:301–8.
- [15]. Nuttall TJ, Thoday KL, van den Broek AH, Jackson HA, Sture GH, Halliwell RE.
- [16]. Retrospective survey of allergen immunotherapy in canine atopy. *Vet Rec.* 1998;143:139–42.
- [17]. Willemsse A, Van den Brom WE, Rijnberk A. Effect of hyposensitization on atopic dermatitis in dogs. *J Am Vet Med Assoc.* 1984;184:1277–80.
- [18]. Schnabl B, Bettenay SV, Dow K, Mueller RS. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. *Vet Rec.* 2006;158:81–5.
- [19]. Cleveland WS, Devlin SJ. Locally-weighted regression: an approach to regression analysis by local fitting. *J Am Stat Assoc.* 1988;83:596–610.
- [20]. Mueller R, Bettenay S. Long-term immunotherapy of 146 dogs with atopic dermatitis—a retrospective study. *Aust Vet Pract.* 1996;26:128–32.
- [21]. Zur G, White SD, Ihrke PJ, Kass PH, Toebe N. Canine atopic dermatitis: a retrospective study of 169 cases examined at the University of California, Davis, 1992–1998. Part II. Response to hyposensitization. *Vet Dermatol.* 2002;13:103–11.
- [22]. Reinero C, Lee-Fowler T, Chang CH, Cohn L, Declue A. Beneficial crossprotection of allergen-specific immunotherapy on airway eosinophilia using unrelated or a partial repertoire of allergen(s) implicated in experimental feline asthma. *Vet J.* 2012;192:412–6.
- [23]. Marogna M, Spadolini I, Massolo A, Zanon P, Berra D, Chiodini E, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. *Ann Allergy Asthma Immunol.* 2007;98:274–80.
- [24]. Buckley L, Schmidt V, McEwan N, Nuttall T. Cross-reaction and cosensitization among related and unrelated allergens in canine intradermal tests. *Vet Dermatol.* 2013;24:422–7.
- [25]. Hauser M, Roulias A, Ferreira F, Egger M. Panallergens and their impact on the allergic patient. *Allergy, Asthma Clin Immunol.* 2010;6:1.
- [26]. Asero R, Jimeno L, Barber D. Preliminary results of a skin prick test-based study of the prevalence and clinical impact of hypersensitivity to pollen panallergens (polcalcin and profilin). *J Investig Allergol Clin Immunol.* 2010;20:35–8.
- [27]. Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. *Vet Dermatol.* 2010;21:456–62.
- [28]. Plant JD, Gortel K, Kovalik M, Polissar NL, Neradilek MB. Development and validation of the canine atopic dermatitis lesion index, a scale for the rapid scoring of lesion severity in canine atopic dermatitis. *Vet Dermatol.* 2012;23:515-e103.
- [29]. Codner E, Lessard P. Effect of hyposensitization with irrelevant antigens on subsequent allergy test results in normal dogs. *Vet Dermatol.* 1992;3:209–14.
- [30]. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. *J Investig Allergol Clin Immunol.* 2007;17:85–91.